In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
Nicholas Piramal has signed an MoU with a French pharma company to manufacture an anti-chikungunya drug.
The bench also cautioned Patanjali Ayurved and its officers from making any statements adverse to any system of medicine in the media, both print and electronic, in any form as they said in their undertaking before the court earlier.
The Drugs Controller General of India has approved the manufacture of this Sars-CoV-2 spike protein recombinant nano-particle vaccine for 'examination, test, and analysis', reports Sohini Das.
The Centre has asked traders and resellers of medical devices to register in an attempt to expand the ambit of regulating the medical devices industry in the country. The move can have far-reaching consequences for both consumers and traders alike as products like face masks or prophylactics - now sold through grocers and other channels - may face issues of availability. In a notification dated September 30, the union ministry of health and family welfare said anyone wanting to sell, stock, exhibit or offer for sale or distribute a medical device, including in-vitro diagnostic medical device, will need a certificate of registration.
Pharmaceutical companies, which are sending across medical aid for flood affected people in Jammu and Kashmir, claim to be facing difficulties in distribution of drugs.
Data also show that several other leading domestic pharma companies have recalled their products from the US
Maria Sharapova will attend an International Tennis Federation anti-doping hearing in London on Wednesday, British media reported, with the Russian facing a possible ban of up to four years for failing a drugs test at the Australian Open.
Reliance Retail Ventures Ltd has acquired a majority equity stake in digital pharma market place Netmeds for a cash consideration of around Rs 620 crore, Reliance Industries said in a late night statement on Tuesday.
The company did not comply to the 'good manufacturing practice' norms.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
The drastic measure will help the company to counter its failure to meet the pricing by generic drug manufacturers.
Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons, as per the latest enforcement report by the US Food and Drug Administration (USFDA). While Aurobindo Pharma is recalling Cyanocobalamin Injection, which is used to treat and prevent lack of vitamin B12, Mumbai-based Sun Pharma is recalling a drug used to increase the production of natural tears in eyes. Similarly, Jubilant Cadista is recalling a drug which is used to treat different inflammatory conditions.
Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market Fosinopril Sodium and Hydrochlorothiazide tablets in 10 mg/12.5 mg and 20 mg/12.5 mg strengths
India's generic drug manufacturer, Dr Reddy's Laboratories, suffered a setback when a US' Court of Appeals ruled that it infringed on Pfizer Pharmaceutical company's patent for the blood pressure medicine Norvasc.
India had the third-largest number of people living with HIV in the world at the end of 2013 and accounts for about four out of 10 people living with HIV in the Asian region.
Voicing concern over many countries failing to vaccinate their people, World Health Organisation chief Dr Tedros Adhanom Ghebreyesus on Thursday called for vaccinating at least 10 per cent of the population of every country by September as he described vaccination as the best way to control the pandemic and reboot the global economy.
As fear grips the world, demand for protective gear used by health care professionals and citizens is on a rise. And, supply disruption from China has opened a window of opportunities for Indian medical device makers.
In a statement on Tuesday, the European Commission said it had requested 'information from certain pharma companies asking them to submit copies of their patent settlement pacts.'
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
The World Health Organisation is reinstating two generic AIDS antiretroviral drugs delisted earlier this year after the Indian manufacturer carried out new studies to confirm that they are as effective as their brand-name counterparts.
The former opener was banned from playing domestic and international cricket after failing to appear at a Bangladesh Cricket Board hearing.\n\n
Nobel laureate Peter Doherty says his 'big worry' is there could be refusals for other vaccines if doubts over its safety turn out to be true.
Whistle-blower Dinesh Thakur tells briefing on US Capitol Hill: 'One in five medicines manufactured and distributed in India are spurious.' Aziz Haniffa reports from Washington, DC.
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
'We need to prove to the world that quality vaccines and R&D are possible in India.'
